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Abstract
Bacterial pathogens can exploit metabolic pathways to facilitate their successful 
infection cycles, but little is known about roles of d- galactosamine (GalN)/ 
N-acetyl- d- galactosamine (GalNAc) catabolism pathway in bacterial pathogenesis. 
Here, we report the genomic reconstruction of GalN/GalNAc utilization pathway 
in Streptococci and the diversified aga regulons. We delineated two new paralo-
gous AgaR regulators for the GalN/GalNAc catabolism pathway. The electro-
phoretic mobility shift assays experiment demonstrated that AgaR2 (AgaR1) 
binds the predicted palindromes, and the combined in vivo data from reverse 
transcription quantitative polymerase chain reaction and RNA- seq suggested 
that AgaR2 (not AgaR1) can effectively repress the transcription of the target 
genes. Removal of agaR2 (not agaR1) from Streptococcus suis 05ZYH33 augments 
significantly the abilities of both adherence to Hep- 2 cells and anti- phagocytosis 
against RAW264.7 macrophage. As anticipated, the dysfunction in AgaR2- 
mediated regulation of S. suis impairs its pathogenicity in experimental models 
of both mice and piglets. Our finding discovered two novel regulators specific 
for GalN/GalNAc catabolism and assigned them distinct roles into bacterial 
infections. To the best of our knowledge, it might represent a first paradigm 
that links the GalN/GalNAc catabolism pathway to bacterial pathogenesis.
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Introduction
Amino sugars are referred to a variety of diversified/com-
plex monosaccharides in which a hydroxyl group is chemi-
cally replaced with the amine group. Most of current 
knowledge on the metabolism of amino sugars comes 
from studies with Escherichia coli (Reizer et al. 1996), 
Bacillus subtilis (Freymond et al. 2006; Gaugue et al. 2014; 
Plumbridge 2015) and Streptomycetes coelicolor (Rigali et al. 
2008). Relative to the best- known examples of amino 
sugars, glucosamine (GlcN) and N- acetylglucosamine 
(GlcNAc), the investigations on the other two amino sugar 
derivatives of galactose, N- acetyl- d- galactosamine (GalNAc) 
and d- galactosamine (GalN), are relatively limited, but 
increasingly accumulated (Abu- Qarn et al. 2008; Leyn 
et al. 2012). It seemed very likely that GalN/GalNAc amino 
sugars as common components participate in the forma-
tion of various cell structures/constitutes in three domains 
of life (Abu- Qarn et al. 2008; Plumbridge 2015). In general, 
not only does GalNAc act as an element of lipopolysac-
charide displayed on bacterial cell wall (Bernatchez et al. 
2005; Leyn et al. 2012), and but also connects carbohydrate 
chains in mammalian mucins (Carraway and Hull 1991). 
Additionally, it functions as the substrate in N- acetyl β- 
galactosidation, a new type of post- translational modifica-
tion of protein in organisms, including bacterial pathogens 
(Sadler et al. 1979; Barr and Nordin 1980; Davis et al. 
1986; Abu- Qarn et al. 2008). Given the multiple roles 
played by GalN/GalNAc, we therefore anticipated a hy-
pothesis that GalN/GalNAc  metabolism might be linked 
to bacterial infectivity.
The paradigm pathway for GalN/GalNAc utilization/
catabolism, which was initially proposed for E. coli in 
1996 (Reizer et al. 1996), contained the following five 
steps (Fig. 1): (1) the transport and phosphorylation of 
GalN/GalNAc substrates (catalyzed by phosphortransferase 
system [PTS] systems AgaBCD and AgaVWEF, respectively) 
(Brinkkotter et al. 2000), (2) the AgaA- mediated deacety-
lation of GalNAc- 6- P (Reizer et al. 1996), (3) the deami-
nation/isomerization of GalN- 6- P by the  bi- functional 
enzyme AgaS into Tag- 6- P (Reizer et al. 1996), (4) the 
AgaZ kinase- aided phosphorylation of Tag- 1,6- P from 
Tag- 6- P (Reizer et al. 1996), and (5) cleavage of Tag- 
1,6- PP by the class II aldolase, AgaY (Brinkkotter et al. 
2002), to produce glyceraldehyde 3- phospahte and glyc-
erone phosphate (PEP). Interestingly, a recent comparative 
genomics- based study suggested an extensive diversity in 
GalN/GalNAc utilization pathways of Proteobacteria such 
as Shewanella (Leyn et al. 2012). In particular note the 
first two steps of this pathway exhibit of high variability, 
while the latter three steps are largely conserved (Leyn 
et al. 2012). In E. coli, not only does AgaR regulator that 
belongs to the DeoR family of transcriptional factors, act 
as an autoregulator, but also negatively controls the ex-
pression of two aga genes (agaZ and agaS) of GalN/
GalNAc catabolism pathway via direct binding of the 
specific palindromes in front of these target genes (Ray 
and Larson 2004). Although the fact that both GalN and 
GalNAc can induce activities of these aga genes- encoding 
protein products is aware, the physiological ligands for 
AgaR repressor remain unclear (Leyn et al. 2012).
Streptococcus suis, a Gram- positive bacterium, is a  zoonotic 
agent with the ability to infect both its natural host swine 
and human individuals with close contact with swine/pork- 
related products (Feng et al. 2010). According to the dif-
ferentiation in their bacterial capsule structure, this 
Streptococcus species is categorized into 35 serotypes (Feng 
et al. 2010, 2014b). Among them, serotype 2 (SS2) is gen-
erally believed to be most virulent, in that it is frequently 
isolated from clinical diseased swine (Ma et al. 2009; Feng 
et al. 2014b) and human sporadic cases (Feng et al. 2009b) 
and/or big- scale outbreaks (Tang et al. 2006; Chen et al. 
2007). We are aware that SS2 has spread to more than 
30 countries/regions and claims nearly 1600 cases of hu-
man infections worldwide (Feng et al. 2014b). The molecular 
mechanism underlying bacterial pathogenicity has been 
partially delineated thus far (Feng et al. 2014b), and these 
identified virulence determinants include the previously- 
known virulence factors exemplified with capsule (Benga 
et al. 2008; Seitz et al. 2014) and suilysin (Jacobs et al. 
1996; Lun et al. 2003; Takeuchi et al. 2014). In addition 
to the regulatory networks amongst the newly identified 
factors (e.g., the two- component systems SalK/SalR [Li et al. 
2008], NisK/NisR [Xu et al. 2014], CiaRH [Li et al. 2011], 
etc.), it would be of particular interest to note the con-
tributions of enzymes from central metabolisms (enolase 
[Eno] [Esgleas et al. 2008; Feng et al. 2009a; Zhang et al. 
2009a; Lu et al. 2012], glutamine synthase [GlnA] [Si et al. 
2009], Inosine 5- monophosphate dehydrogenase [Impdh] 
[Zhang et al. 2009b; Zhou et al. 2014], etc.) to bacterial 
pathogenesis (Feng et al. 2014b). However, nothing is aware 
regarding the potential relevance of bacterial GalN/GalNAc 
metabolism and/or its regulation to S. suis infection.
In this work, we employed the integrative approaches 
combining the bioinformatics and comparative genomics 
to conduct the genomic reconstruction of the GalN/GalNAc 
utilization pathway in Lactobacillaceae, including the  zoonotic 
pathogen S. suis. Also, we are the first to report the func-
tional definition of two new GntR- type transcription factors 
(referred to AgaR2 and/or AgaR1) with involvement of 
GalN/GalNAc catabolism. More intriguingly, we observed 
that AgaR2- dependent regulation of GalN/GalNAc utiliza-
tion pathway is required for bacterial virulence of S. suis 
serotype 2. To the best of our knowledge, it represents 
the first example that the genetic control of GalN/GalNAc 
catabolism is linked to bacterial infectivity of Streptococcus.
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Materials and Methods
Bacterial strains, cell lines and growth 
conditions
Bacterial strains used here included derivatives of either 
E. coli or S. suis 2 (Table S1). Escherichia coli Topo10 
and BL21 (DE3) are applied for gene cloning, and protein 
 expression, respectively. The growth medium for E. coli 
and S. suis 2 is separately Luria- Bertani (LB) broth and 
Todd- Hewitt broth (THB; Difco Laboratories, Detroit, 
MI). These bacteria are grown at 37°C overnight. Given 
the selective pressure to ensure the replication of recom-
binant plasmids or the maintenance of engineered strains, 
appropriate antibiotics (Sigma, St. Louis, MO) were sup-
plemented as follows: 100 μg/mL of Spectinomycin for 
S. suis; either 100 μg/mL of Ampicillin or 50 μg/mL of 
Kanamycin for E. coli. The two kinds of cell lines used 
Figure 1. Reconstruction for GalNAc/GalN utilization pathways in Streptococcus suis. The variants of GalNAc/GalN pathway in Escherichia coli and S. 
suis are highlighted with yellow and light- blue background arrows, respectively. GalNAc, N- acetyl- d- galactosamine; GalN, galactosamine; PTS, 
phosphotransferase system; BgaC, β- galactosidase; AgaA, GalNAc- 6- P deacetylase; AgaS, GalN- 6- P deaminase/isomerase; Tag, Tagtose; AgaZ, Tag- 
6- P kinase; AgaY, Tag- 1,6- PP aldolase.
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here corresponded to the human laryngeal epithelial cell 
Hep- 2 (CCTCC GDC004) and the mouse macrophagocyte 
Raw 264.7 (ATCC TIB- 71, Rockville, MD), respectively 
(Table S1) (Hu et al. 2014), and cultivated at 37°C in 
the presence of 5% CO2 in Dulbecco’s modified Eagle’s 
medium with 10% fetal bovine serum (Roche, Indianapolis, 
IN, USA),100 μg/mL gentamycin, and 5 μg/mL penicillin 
G (Feng et al. 2012).
Plasmids and DNA manipulations
The S. suis agaR2 (SSU05_0447) gene was amplified 
using polymerase chain reaction (PCR) with primers 
SSU05_0447- F plus SSU05_0447- R (Table S2) and ligated 
into the BamHI and XhoI sites of pET28a(+) expres-
sion vector (Feng et al. 2008), resulting in the 
recombinant plasmid pET28-447 (Table S1). Similarly, 
the other expression plasmid pET28-448 was given 
through direct cloning of S. suis agaR1 (SSU05_0448) 
gene carrying BamHI and SalI sites introduced by prim-
ers (SSU05_0448- F plus SSU05_0448- R) into the expres-
sion vector pET28a(+) with the same cuts (Tables S1, 
S2). The above two plasmids (pET28-447 and pET28-
448) are designed to prepare in vitro proteins of AgaR2 
and AgaR1, respectively. For functional complementa-
tion, the two genes (SSU05_0447 and SSU05_0448) were 
separately inserted into the low- copy shuttle vector 
pVA838 (Romero et al. 1987), giving the plasmids 
pVA838- 447 and pVA838- 448, respectively (Table S2). 
All the recombinant plasmids involved in this study 
were confirmed with both PCR assays and direct DNA 
sequencing.
Figure 2. Discovery of the genome- wide regulons encoding the GalNAc/GalN utilization pathways in Lactobacillales Arrows represent the GalNAc/
GalN catabolism- related genes, and circles denote the predicted AgaR- recognizable sites. The genes are variably colored according to differential 
functions assigned in Figure 1 and labeled with the last letter of the corresponding protein. Genes from the same genetic loci that are not adjacent/
neighbored each other are separated by a slash. Similarly, genes from different genetic loci are separated by a double slash. Given the two types of 
putative AgaR- binding palindromes shown on the top (details in Table S4), AgaR1 and AgaR2 sites are accordingly colored with red and blue. 
Sequence logos were given using the WebLogo package (http://weblogo.berkeley.edu/logo.cgi). The detailed information on the displayed loci is 
listed in Table S3 and Figure S4. GalNAc, N- acetyl- d- galactosamine; GalN, galactosamine.
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Expression and purification of two AgaR 
proteins
The two recombinant plasmids (pET28a- 448 and pET28a-
 447) were separately transformed into BL21 (DE3), giving 
the engineered strains FYJ356, and FYJ536, respectively (Table 
S1). The two versions of hexahistidine- tagged AgaR protein 
(referred to AgaR1 [SSU05_0448] and AgaR2 [SSU05_0447]) 
were produced using the above two engineered strains FYJ356 
and FYJ536, respectively. In brief, when bacterial optical 
density at wave- length of 600 nm (OD600) reached 0.6–1.0, 
the bacterial cultures with an appropriate plasmid (Table 
S1) were induced with 0.5 mmol/L isopropyl- β- d- 
thiogalactopyranoside (IPTG) at 30°C for 3–5 h. As we 
described before (Feng and Cronan 2009), two rounds of 
French pressure- based lysis were conducted for release of 
the recombinant protein AgaR1 (and/or AgaR2), and sub-
sequent procedures of protein purification included the 
nickel column- based affinity purification followed by fast 
phase liquid chromatography (FPLC) (Feng et al. 2008; Feng 
and Cronan 2012). Consequently, the protein of interest 
was concentrated via ultrafiltration (Feng et al. 2008), and 
the purity was judged by 12% sodiumdodecyl sulfate poly-
acrylamide gel electrophoresis (SDS- PAGE).
Western blotting
Western blot was performed routinely to further verify 
the hexahistidine-tagged AgaR1 (and/or AgaR2) protein. 
The protein samples were separated with 12% SDS- PAGE 
and thereafter transferred to a nitrocellulose membrane 
(Amersham, GE Healthcare, Piscataway, NJ, USA). The 
primary antibody was an anti- hexahistidine mouse mono-
clonal antibody, and the secondary antibody was a 
peroxidase- conjugated goat anti- mouse immunoglobulin 
G. The signal of target protein band was captured by an 
exposure to the  high- performance chemiluminescence ECL 
film (Amersham, GE Healthcare, Piscataway, NJ, USA).
Liquid chromatography quadrupole time- of- 
flight mass spectrometry
To verify the identity of the recombinant AgaR1 (and/
or AgaR2), the resultant peptides by digestion with 
Sequencing Grade Trypsin (G- Biosciences, St. Louis, MO, 
12.5 ng μL−1 in 25 mmol/L ammonium bicarbonate) were 
subjected for analyses of A Waters Q- Tof API- US Quad- 
ToF mass spectrometer linked to a Waters nano Acquity 
UPLC (Feng et al. 2013b). The mass data acquired were 
assayed through Waters Protein Lynx Global Server 2.2.5, 
Mascot (Matrix Science, Boston, MA, USA) combined 
with BLAST against NCBI nr database (Feng et al. 2014a).
Size exclusion chromatography and chemical 
cross- linking assays
The nickel column- based purified AgaR1 (and/or AgaR2) 
protein was further assayed by gel filtration chromatography 
using a Superdex 75 column (Amersham, GE Healthcare, 
Piscataway, NJ, USA) run on an Äkta fast protein liquid 
chromatography system (GE Healthcare) as described 
Figure 3. Maximum- likelihood phylogenetic tree of AgaR proteins. AgaR1 (SSU05_0448) is given in red, and AgaR2 (SSU05_0447) is highlighted in 
blue. The NagR proteins from Bacillus subtilis, Streptococcus suis, and Lactobacillus plantarum are used as outtree. The logos for the predicted 
palindromes recognized by AgaR1 (AgaR2) is presented on the right hand. All the homologs of AgaR1 (AgaR2) is accessed to Table S3. NagR proteins 
from B. subtilis 168 (Bertram et al. 2011), L. plantarum WCFS1, and S. suis 05ZYH33 were used as an outgroup. NagR was selected because, as like 
AgaR1 and AgaR2, this protein is a member of the HutC subfamily of the GntR family and a regulator of aminosugar metabolism.
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previously (Feng and Cronan 2010, 2011). The column ef-
fluent was evaluated at a flow rate of 0.5 mL/min in PBS 
buffer (10 mmol/L Na2HPO4, 2 mmol/L KH2PO4, 20 mmol/L 
Tris- HCl, 137 mmol/L NaCl, 2.7 mmol/L KCl, pH 7.4). 
The protein peak at the position of expected elution volume 
was sampled and verified by 12% SDS- PAGE.
To further elucidate the solution structure of AgaR1 
(and/or AgaR2) protein from S. suis, we conducted chemi-
cal cross- linking experiments in which ethylene glycol 
bis- succinimidylsuccinate (EGS) (Pierce, Rockford, IL, 
USA) was added (Feng et al. 2008). In each reaction 
system (15 μL in total), the interested protein (~5 mg/
mL) was separately incubated with the EGS cross- linker 
(at different levels [0.1, 0.2, 0.5, 1.0, 2.5, 5, 10, 20 μmol/L 
for AgaR1 protein; 0, 2.5, 5, 10, 20 μmol/L, for AgaR2 
protein]) for 1 h at room temperature. Finally, the reac-
tion products were visualized via 12% SDS- PAGE followed 
by commassiee brilliant blue staining.
Electrophoretic mobility shift assays
The function of the predicted AgaR2 and AgaR1 binding 
sites were proved using electrophoretic mobility shift assays 
(EMSA) as we established earlier (Feng and Cronan 2011; 
Feng et al. 2013a,b) with minor modifications. All the double- 
strand DNA probes were produced in vitro by annealing 
two complementary oligonucleotides in TEN buffer 
(10 mmol/L Tris- HCl, 1 mmol/L Ethylene Diamine Tetraacetic 
Acid (EDTA), 100 mmol/L NaCl; pH 8.0), and labeled with 
DIG- ddUTP (Roche, Indianapolis, IN, USA) by the terminal 
transferase (Feng and Cronan 2011, 2012). Three AgaR1- 
specific DNA probes used here included SSU05_0448/9 site1 
probe (38 bp), EF814 site1 probe (38 bp), and EF1809 site1 
probe (38 bp). In addition to SSU05_0447 probe (36 bp) 
as the negative control, the other four tested AgaR2- 
recognizable sites corresponded to SSU05_0195 probe (36 bp), 
SSU05_1259 probe (36 bp), 5 SSU05_0448/9 site2 (36 bp), 
and EF1809 site2 probe (36 bp) (Table S2). After 20 min 
of incubation of the DIG- labeled DNA probes (0.2 pmol) 
with or without AgaR2 (and/or AgaR1) protein in the bind-
ing buffer (Roche) at room temperature, the DNA–protein 
complexes were separated by the native 7% PAGE gel and 
transferred onto an equilibrated, positively charged nylon 
membrane (Roche) by contact blotting followed by UV 
cross- linking (120 mJ for 180 sec) (Feng and Cronan 2011; 
Feng et al. 2013b). Finally, the signals were captured by 
exposure to the high- performance chemiluminescence film 
(Amersham Hyperfilm ECL) (Feng and Cronan 2009, 2010).
RNA isolation and real- time qPCR
Mid- log phase cultures of S. suis 2 strains (wild type [WT], 
ΔagaR1, ΔagaR2, CΔagaR1 and CΔagaR2) grown in THB 
media (with/without GalNAc- 6P) were collected to prepare 
Figure 4. Preparation, identification, and characterization of the AgaR2 
(SSU05_0447) protein. (A) 12% SDS- PAGE profile of the purified AgaR2 
(SSU05_0447) protein from Streptococcus suis. The protein with 
expected size (~31 kDa) is indicated with an arrow. “M” is the 
abbreviation for protein molecular weight. The numbers on left hand 
represent protein size (kDa). 1, crude extract of Escherichia coli lysate 
expressing the recombinant AgaR2 protein; 2, the purified form of the 
recombinant AgaR2 protein. (B) Western blotting analyses for the N- 
terminal 6x his tagged AgaR2 protein using the anti- 6xHis tag primary 
antibody. WB, western blot; 1, the crude extract of E. coli lysate 
expressing the recombinant AgaR2 protein; 2, the purified form of 
AgaR2 protein. (C) Chemical cross- linking assays for the solution 
structure of the AgaR2 protein. The chemical cross- linker used here is 
EGS. The triangle on the top represents the addition of EGS cross- linker 
in varied concentrations (0, 2.5, 5, 10, 20 μmol/L in the right- hand five 
lanes [left to right]). (M) Molecular weight. The molecular weight of the 
monomeric AgaR2 protein is estimated to be ~31 kDa, and the dimeric 
form is ~62 kDa. The protein sample was judged with 12% SDS- PAGE. 
(D) MS- based identification of the purified AgaR2 protein. The tryptic 
peptides with hits to the AgaR2 sequence are given in bold and 
underlined type. SDS- PAGE, sodiumdodecyl sulfate polyacrylamide gel 
electrophoresis; EGS, ethylene glycol bis- succinimidylsuccinate.
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the total bacterial RNA using an RNeasy bacterial RNA 
isolation kit (Qiagen, Hilden, Germany) (Feng et al. 2008; 
Li et al. 2008). As we performed before (Feng and Cronan 
2009, 2010), RNA integrity/quality was validated by separa-
tion of 1.0% agarose gel electrophoresis. The possible 
contamination of trace genomic DNA in the RNA samples 
was ruled out by PCR- based detections, using the total 
RNA as the template (Feng and Cronan 2009, 2010, 2011).
Using the qualified RNA preparations, complementary 
DNAs (cDNAs) were synthesized by reverse transcription 
(RT). Then, the real- time quantitative PCR (qPCR) 
combined with the SYBR green method (Feng et al. 
2008; Feng and Cronan 2009) was carried out to probe 
possible relevance of agaR2 (and/or agaR1) to the altered 
expression profile of genes encoding GalNAc utilization 
pathway. The method of 2−ΔΔCT (34) was applied to 
determine the relative level of the target genes associ-
ated with GalNAc utilization in which the 16S rRNA- 
encoding gene 16S rDNA as the internal reference (Table 
S2). Target genes tested here are agaS (SSU05_0195), 
Figure 5. Binding of AgaR2 to the predicted cognate sites. Alignment of the AgaR2- binding sites from species of Lactobacillales (A) and the resulting 
sequence logo (B). In (A) the identical residues are white letters in red background, similar residues are black letters in yellow background, and varied 
residues are in black letters. Names and locus tags for genes from Streptococcus suis are shown by red font. In (B) the sequence logo is generated 
using WebLogo (http://weblogo.berkeley.edu/logo.cgi). The detailed information of the cognate sites is seen in Table S4. (C) AgaR2 does not bind its 
own promoter. (D) Binding of agaS (SSU05_0195) promoter to AgaR2 proteinInteraction of AgaR2 protein with the promoter regions of both agaA 
(SSU05_1259) (in E) and bgaC (SSU05_0449) (in F) AgaR2 protein from Streptococcus suis cannot bind to the AgaR1 site of EF1809 of Enterococcus 
faecalis V583 (in G), whereas it binds to its AgaR2 site (in H). The minus sign denotes no protein of AgaA2 added. The protein levels of AgaR2 (in the 
right hand four lanes of each panel [left to right]) were 0.5, 1, 2 and 5 pmol. The protein samples were incubated with 0.2 pmol of DIG- labeled probe 
in a total volume of 20 μL. A representative result from three independent gel shift assays (7% native PAGE) is given.
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agaAY (SSU05_1258/9), bgaC (SSU05_0449), and gad-
VWEF (SSU05_0450, SSU05_0451, SSU05_0452 and 
SSU05_0453), respectively.
Construction of ΔagaR2 (and ΔagaR1) 
mutants and functional complementation
The agaR2 (or agaR1) gene from the S. suis 2 strain 
05ZYH33 was replaced with the spectinomycin resistance 
(SpcR) cassette by homologous recombination (Feng et al. 
2008, 2012; Hu et al. 2014). Briefly, the SpcR cassette 
from pSET2 (Takamatsu et al. 2001) was cloned into the 
pUC19 vector (Invitrogen) to give the intermediate plasmid 
pUC19- Spc (Table S1), and then the two DNA fragments 
adjacent to the agaR2 (or agaR1) gene were separately 
inserted into the pUC19- Spc vector, giving the knockout 
plasmid pUC::447 and pUC::448, respectively (Table S1). 
As we did before (Feng et al. 2008; Li et al. 2008), the 
plasmid of pUC::447 (or pUC::448) was electroporated 
into the competent cells of S. suis 05ZYH33 to acquire 
positive transformants with SpcR. The multiplex- PCR 
techniques were adopted to screen the ΔagaR2 (and/or 
ΔagaR1) mutant (Table S2). Consequently, the mutants 
we acquired for functional experiments were further proved 
by direct DNA sequencing. The two plasmids of pVA838-
447 and pVA838-448 were separately transformed into 
ΔagaR2 and ΔagaR1 mutants to give the complemented 
strains CΔagaR2 and CΔagaR1, respectively (Table S2).
Assays for ability of bacterial adherence and 
phagocytosis
As Hytönen et al. (Hytonen et al. 2006) reported, S. suis 
bacteria (WT, ΔagaR2 and CΔagaR2) grown in the mid- 
log phase were subjected to cell lines- based analyses. The 
two cell lines are Hep- 2 (human laryngeal epithelial cell 
line) and murine macrophage Raw 264.7 cells (Feng et al. 
2012; Hu et al. 2014). Bacterial adherence was tested with 
Hep- 2 cell line, and the evaluation for ability of anti- 
phagocytosis was based on the Raw264.7 cells.
Infection assays of experimental animals
To reveal the role of agaR2 (and/or agaR1) in bacterial 
pathogenesis/virulence, two different kinds of experimental 
animals were employed, including BALB/c (4- week old, 
female) mice and SPF- piglets. In the infection experiment 
of mice, totally 60 animals were challenged that are clas-
sified into six groups (10 mice/group). Except that THB 
acted as a negative control, the other five groups infected 
with S. suis 2 (at a dose of 1 × 108 CFU per mouse) 
corresponded to WT, ΔagaR2, CΔagaR2, ΔagaR1, and 
CΔagaR1, respectively.
The result obtained from the experiment of mice infec-
tion was further checked using the infection test of piglets, 
its natural host of S. suis. Given the fact that only agaR2 
(not agaR1) plays a role in bacterial infectivity, three 
groups of piglets (six piglets/group) were rechallenged by 
WT, ΔagaR2, and CΔagaR2, respectively. Clinical syn-
dromes of the infected mice/piglets were monitored for 
72 h. Of particular note, deaths were recorded and mori-
bund animals were humanely killed. All experiments on 
live vertebrates in this study were approved by the Ethics 
Figure 6. GalNAc/GalN utilization pathway is repressed by AgaR2 and 
induced by addition of GalNAc. (A) Schematic diagram for agaR2 and its 
cognate target genes.Circles denote the AgaR2- recognizable sites, and 
the arrows represent the genes of the GalNAc utilization pathway. 
Note: SSU05_1259 and SSU05_1258 constitutes an operon agaAY, 
whereas the four ordered genes (SSU05_0449, SSU05_0450, 
SSU05_0451, and SSU05_0452) might form an operon of bgaC- 
gadVWEF. (B) Real- time qPCR assays for effects of agaR2 on expression 
profile of genes of GalNAc/GalN utilization pathway in Streptococcus 
suis. (C) Addition of GalNAc increases expression level of GalNAc/GalN 
utilization pathway- encoding genes in S. suis.The data are expressed as 
averages ± SD, and error bars mean SD. No less than five independent 
experiments were carried out here. The minus sign denotes no addition 
of GalNAc into growth media, whereas the plus sign denotes addition 
of GalNAc in vitro. Note: P < 0.005. GalNAc, N- acetyl- d- galactosamine; 
GalN, galactosamine; qPCR, quantitative PCR; SD, standard deviations. 
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Committee of Research Institute for Medicine of Nanjing 
Command and performed in accordance with the relevant 
guidelines and regulations (Cao et al. 2011; Feng et al. 
2012; Hu et al. 2014).
Bioinformatics analyses
Genome sequences were downloaded from the 
MicrobesOnline genomic data base (Dehal et al. 2010). 
Identification of orthologs was performed using the 
BLASTP search in the non- redundant database (Altschul 
et al. 1997) and MicrobesOnline tree browser. For func-
tional protein annotations by distant homology to char-
acterize proteins, BLAST search in the SwissProt/UniProt 
database was used. Analysis of chromosomal gene clustering 
was performed by MicrobesOnline and SEED web resources 
(Dehal et al. 2010; Disz et al. 2010). The GalNAc utiliza-
tion subsystem curation and analysis were conducted, using 
the SEED platform (Disz et al. 2010). Protein domains 
were determined by protein similarity search tools in the 
Pfam database (Sonnhammer et al. 1998). Multiple se-
quence alignments were constructed by either ClustalW 
(http://www.ebi.ac.uk/Tools/clustalw2/index.html) 
(Thompson et al. 2002) or MUSCLE (Edgar 2004). 
Phylogenetic trees were constructed using the maximum 
likelihood algorithm implemented in the PHYLIP package 
(Felsenstein 1996) and visualized via the dendroscope tool 
(Huson et al. 2007). Sequences Logos were constructed 
using WebLogo package (Crooks et al. 2004).
For genomic reconstruction of the regulons, we used 
the well- established comparative genomics approach 
(Rodionov 2007). The approach includes inference of 
transcriptional factor- binding sites (TFBSs), construction 
of nucleotide positional weight matrices (PWMs) for 
TFBSs motifs, and reconstruction of regulons in complete 
genomes on the basis of prediction of putative TFBSs 
in the promoter gene regions. First, in the studied 
Lactobacillales genomes, we revealed orthologs of previ-
ously known genes for GalNAc utilization (Table S3). 
Second, we predicted possible transcriptional regulators 
for the uncovered GalNAc utilization. Candidate regula-
tors were attributed to the regulons by using a genomic 
colocalization and co- occurence of a putative regulator 
with the identified GalNAc utilization genes. Such analysis 
defined two groups of transcriptional regulators belonging 
to the HutC subfamily of the GntR family (Fig. 7). For 
each group of AgaR proteins, we identified putative  binding 
motifs analyzing upstream regions of presumably regulated 
gene by the Discover Profile tool implemented in the 
RegPredict Web server (Novichkov et al. 2010). In this 
approach, putative TFBSs were determined as overrep-
resented words in upstream regions of putatively co- 
regulated genes. Based on the genomic co- occurrence and 
co- presence of genes, it has been proposed that AgaR1- 
binding sites should be located upstream hydrolase and 
PTS genes while AgaR2 sites ought to be upstream of 
deacetylase, isomerase, and aldolase genes. For the pre-
diction of putative TFBSs, we analyzed upstream regions 
of probably related operons, expanding −400 to +100 bp 
relative to start codon of the first gene of the operon. 
Both AgaR1 and AgaR2 belong to HutC subfamily. TFBSs 
for HutC subfamily proteins have structure of an even 
palindrome (Rigali et al. 2002; Suvorova et al. 2015). 
Thus, for prediction of the AgaR1 and AgaR2 TFBSs 
motifs, we searched for even palindromic DNA motifs 
of 14–24 bp. Among all motifs found for each set of 
upstream regions, we selected the longest motif with the 
highest information content. The selected motif was qual-
ity controlled by two approaches, (1) consistency check 
and (2) phylogenetic footprinting. Consistency check 
(Mironov et al. 1999; Rodionov 2007) was done, that 
is, motif was checked for the presence in multiple number 
of genomes. High quality motif should find predicted 
TFBSs in upstream regions of predicted regulated operons 
in genomes having the analyzed regulator, but not in 
genomes lacking the regulator. Phylogenetic footprinting 
technique is based on analysis of multiple alignments 
for upstream regions of orthologous genes (Shelton et al. 
1997). High quality motif should find predicted TFBSs 
that are located inside conserved islands of multiple align-
ments. When the high quality of the motif was confirmed 
by both consistency check and phylogenetic footprinting, 
the identified regulatory motifs were used for the con-
struction of the PWMs (profiles) and the obtained matrices 
were used to determine additional candidate regulatory 
sites in the analyzed genomes, using the Run Profile tool 
in the RegPredict Web server. The scores of sites were 
calculates as a sum of nucleotide weights for each 
position.
Statistics
The data used here were expressed as mean ± SD. Unless 
specified, data were analyzed by two- tailed, unpaired t 
test, and all assays were repeated no less than three times. 
The threshold for significance refers to the P < 0.05.
Results
Reconstruction of the GalNAc utilization 
pathway in Lactobacillaceae
The GalNAc utilization pathway has been previously re-
constructed by the comparative genomics approach in a 
large number of Proteobacteria species (Leyn et al. 2012) 
and experimentally analyzed in E. coli (Brinkkotter et al. 
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2000) and Shewanella sp. ANA- 3 (Leyn et al. 2012). Here 
we used the same approach for reconstruction of the 
GalNAc utilization pathway in the zoonotic agent, S. suis 
(Fig. 1 and Table S1). For integrated genomic reconstruc-
tion of GalNAc utilization pathways and concordant tran-
scriptional regulation, we searched orthologs of known 
GalNAc utilization genes (Leyn et al. 2012) in complete 
Lactobacillales genomes. As a result, the genes encoding, 
this metabolic pathway was identified in 16 genomes rep-
resenting four families, Streptococcaceae, Lactobacillaceae, 
Enterobacteraceae, and Carnobacteriaceae (Table S1). The 
minimal number of genes in the reconstructed regulons 
was detected in Lactobacillus helveticus and Streptococcus 
pyogenes. In these organisms, only one or two genes from 
the GalNAc utilization pathway were found because these 
genes were insufficient for GalNAc utilization. Most prob-
ably, these organisms cannot utilize GalNAc. The minimal 
gene set allowing utilization of GalNAc is present in a 
group of closely related genomes including Streptococcus 
gordonii, Streptococcus mitis, and Streptococcus pneumonia. 
This gene set contains genes for regulator (agaR), 
galactosamine- 6- phosphate deaminase/isomerase (agaS), 
glycoside hydrolase (bgaC), and PTS (gadVWEF). The 
other well- studied Streptococcus genomes also contain genes 
for the tagatose- 1,6- diphosphate aldolase (agaY). In con-
trast, all the analyzed Lactobacillus lack agaY gene but 
contain the gene for N- acetylgalactosamine- phosphate 
deacetylase (agaA). Amongst Streptococcaceae, agaA gene 
was identified only in the S. suis genome. The gene for 
tagatose- 6- phosphate kinase (agaZ) was found only in 
Enterococcus faecalis and Carnobacterium sp. 17- 4.
Previously agaY gene was shown to be not obligatory 
for the GalNAc utilization and function of agaZ was pro-
posed to be actualized by other genes, such as lacC (EC 
2.7.1.144) or pfk (EC 2.7.1.11). Orthologs of these genes 
were found in the studied genomes, for example in S. 
suis LacC is encoded by gene with locus tag SSU05_1041 
and Pfk is encoded by SSU05_0543.
The presence or absence of agaA gene is the crucial 
point for the ability or disability to utilize GalNAc. 
Thus, the absence of this gene in the Aga regulons 
points to the ability of the organism to utilize only 
GalN, but not GalNAc utilization. Thus, organisms lack-
ing agaA gene should have GalN- specific transporters 
whereas organism having agaA gene should be able to 
transport GalNAc (Leyn et al. 2012). To predict the 
specificity of the Lactobacillaceae transport systems, we 
compared all the identified PTSs to the previously de-
scribed ones. The phylogenetic analysis revealed that all 
the Lactobacillaceae PTSs are orthologous to the transport 
system from Haemophilus parasuis (Fig. S4). This PTS 
was previously proposed to be specific to GalN- containing 
oligosaccharides. Co- occurrence and co- localization of 
this PTS with the hydrolase genes in the most studied 
genomes confirms its specificity to the oligosaccharides. 
On the other hand, PTS genes are co- localized also 
with the agaA gene in the large number of studied 
genomes (Table S3) that designate to the possibility of 
this system to transport GalNAc or both GalNAc and 
GalN containing oligomers. However, we cannot have 
success in predicting the precise specificity of the gad-
VWEF encoded PTS, using only the comparative genomics 
approach.
Comparative genomics- based insights into 
the regulation of GalNAc utilization in 
Lactobacillales
For the integrated genomic reconstruction of GalNAc 
utilization pathways and the concordant transcriptional 
regulation, we searched orthologs of known GalNAc 
utilization genes (Leyn et al. 2012) in complete 
Lactobacillales genomes. As a result, the genes encoding 
this metabolic pathway were identified in 16 genomes 
representing four families, Streptococcaceae, 
Lactobacillaceae, Enterobacteraceae, and Carnobacteriaceae 
(Table S3). Analysis of conserved chromosomal loci with 
the GalNAc utilization genes detected the presence of 
one or two suggested transcriptional regulators per ge-
nome (Fig. 2 and Table S3). All predicted regulators 
belong to the GntR family of transcription factors 
(Hoskisson and Rigali 2009). Phylogenetic analysis re-
vealed that the predicted regulators form two separate 
orthologous groups that we named AgaR1 and AgaR2 
(Fig. 3). A strong tendency of agaR1 and agaR2 genes 
to cluster onto the chromosome with the GalNAc uti-
lization genes suggests conservation of their function 
(Fig. 2). Two Lactobacillaceae and four Streptococcaceae 
genomes have both agaR1 and agaR2 genes, whereas in 
other genomes only one of the regulator genes was pre-
sent (Fig. 2 and Table S3).
To infer the AgaR1/AgaR2 regulons in Lactobacillales, 
we used the comparative genomics approach applied in 
the RegPredict Web server. This approach combines 
prediction of candidate regulator- binding sites with cross- 
genomics comparison of regulons. Since AgaR1 and 
AgaR2 protein orthologous groups are distantly related 
to each other (30% identity), we propose that their 
binding motifs should also be different. In most analyzed 
genomes, agaR1 is co- localized with genes for glycoside 
hydrolase and PTS, whereas agaR2 tends to be clustered 
onto the chromosome with the genes for deacetylase, 
isomerase, and aldolase (Fig. 2 and Table S3). Thus, 
we proposed that AgaR1- binding sites should be located 
upstream hydrolase and PTS genes while AgaR2 sites 
ought to be upstream of deacetylase, isomerase, and 
11© 2015 The Authors. MicrobiologyOpen published by John Wiley & Sons Ltd. 
Two Novel Regulators of GalNAc Utilization PathwayH. Zhang et al.
aldolase genes. Upstream regions of genes presumably 
regulated by each transcriptional factor were analyzed 
using Discover Profile tool of the RegPredict Web re-
source. After the identification of putative- binding motif, 
we searched for additional regulatory sites in the analyzed 
genomes and finally reconstructed AgaR1 and AgaR2 
regulons.
The candidate motifs for both the studied regulators have 
an even palindrome structure (Figs. 2, 5A and Table S4) 
that is in good agreement with previous observations on 
binding motifs for proteins of the HutC subfamily of GntR 
family (Hoskisson and Rigali 2009). Predicted AgaR1- binding 
sites have a length 20 bp, whereas the predicted- binding 
sites for AgaR2 are 18 bp sequences (Fig. 5A and Table 
S4). Both AgaR1 and AgaR2- binding motifs have a palin-
drome AT- rich central part. The AgaR1- binding motif is 
AT- rich at all times and quite degenerated, that is, has 
moderate information content. On the other hand, the 
AgaR2- binding motif is more CG- rich and conserved and 
has a higher information content than AgaR1- binding motif. 
Additionally, AgaR2- binding motif demonstrate similarities 
with the motifs of some regulators, previously characterized 
experimentally or in silico, such as GnbR of Lactobacillus 
casei BL23 (Bidart et al. 2014) and NagR proteins of B. 
subtilis (Bertram et al. 2011; Leyn et al. 2013) and various 
Lactoacillales (Ravcheev et al. 2013). Composition of the 
AgaR1 and AgaR2 regulons varies between species (Fig. 2). 
In Lactobacillus rhamnosus (L. rhamnosus), Enterococcus faecalis 
(E. faecalis), and Carnobacterium sp. 17- 4, all genes for 
GalNAc utilization are organized in a single operon that is 
regulated by a single regulator, AgaR2 in the first two ge-
nomes and AgaR1 in the last one (Fig. 2 and Table S3). 
In the most part of the Streptococcaceae and Lactobaciilaceae 
genomes, we observed a strong “division of labor” between 
the two regulators (Fig. 2). Thus, AgaR1- binding sites were 
found upstream of hydrolase/PTS genes, whereas AgaR2 
looks to regulate genes for deacetylase/isomerase/aldolase 
(Fig. 2). In the genomes of S. suis, Lactobacillus gasseri (L. 
gasseri) and Lactobacillus johnsonii (L. johnsonii), overlapping 
of regulons was detected (Fig. 2). In all these genomes, 
genes for the transport system seemed likely to be under 
double regulation by AgaR1 and AgaR2. Also, in the vast 
majority of the analyzed genomes autoregulation was identi-
fied for both agaR1 and agaR2 genes (Table S4).
Characterization of AgaR1 and AgaR2, two 
novel GntR- type regulators
To probe the putative function of the two new members 
(S. suis AgaR2 and AgaR1) of the GntR family of tran-
scription factors, we employed BL21(DE3)/pET28(a) a 
prokaryotic expression system to prepare the above two 
proteins in vitro. Consequently, the N- terminal 
hexahistidine tagged S. suis AgaR2 protein was purified 
to homogeneity and gave a single- protein band of ap-
propriate molecular mass (~31 kDa for monomer) 
(Fig. 4A). The 6xHis tagged version of this recombinant 
S. suis AgaR2 protein was also determined by Western 
blot using the anti- 6xHis tag primary antibody (Fig. 4B). 
Chemical cross- linking assays with the EGS cross- linker 
visualized clearly the EGS dose- dependent dimerization 
of AgaR2, indicating its predominant solution structure 
of this protein is a dimer (Fig. 4C). Liquid chromatog-
raphy mass spectrometry- based determination of tryptic 
peptides of the recombinant AgaR2 protein band excised 
from an SDS- PAGE gel (Fig. 4A) verified its identity, in 
that the peptides matched S. suis SSU05_0447 protein 
with 77% coverage of the expected peptides (Fig. 4D).
Somehow different from the AgaR2 protein, two forms 
of AgaR1 protein (monomer, the predominant form, and 
trace amount of dimer) still can be detected by the sepa-
ration with 12% SDS- PAGE (Fig. S2A). Given that two 
possibilities are present (either the contaminated protein 
with the molecular mass at the dimeric position, or the 
dimeric form of AgaR1), Western blotting with the anti- 
6xHis tag primary antibody was conducted. As anticipated, 
it clearly showed that two protein bands with an ap-
propriate molecular mass (~31 kDa for monomer and 
~60 kDa for dimer), ruling out the possibility of protein 
contamination (Fig. S2B). This observation is unexpected, 
but not without precedent. In fact we recently encountered 
a similar scenario in the case of the Brucella BioR regula-
tor that is also a member of the GntR family transcription 
factor (Feng et al. 2013a). The essence of BioR1 forming 
a dimer was further proved by chemical cross- linking as-
says (Fig. S2C). MS- based analyses of two protein bands 
of AgaR1 (one is cut from a dimer, the other is collected 
from a monomer) validated exactly the identity wherein 
the two forms of peptides covered S. suis SSU05_0448 
protein at the level of no less than 80% (Fig. S2D and 
E).
Streptococcus suis AgaR2 (AgaR1) binds the 
predicted cognate palindromes
It seemed very likely that the genome of S. suis 05ZYH33 
(Accession no.: CP000407.1) encodes a fully functional 
GalNAc utilization machinery and most of the genes en-
coding this pathway are regulated by AgaR2 (and/or AgaR1) 
(Fig. 1). Thereby, we employed EMSA to probe the bind-
ing of the AgaR2 (and/or AgaR1) protein to the cognate 
palindromes (Table S4, Fig. 5A and B). On the S. suis 
chromosome, totally three putative AgaR2- binding sites 
(SSU05_0195 probe, SSU05_1259 probe and SSU05_0448/9 
site 2 probe) were localized, whereas only one possible 
AgaR1- recognizable site (SSU05_0448/9 site 1 probe) was 
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detected. Because of the absence of the predicted AgaR2- 
binding site upstream of the agaR2 gene, we expected 
that this gene is not autoregulated. Indeed, EMSA experi-
ments suggested that AgaR2 protein cannot bind to its 
own promoter region (SSU05_0447 probe), ruling out the 
possibility of autoregulation by AgaR2 regulator (Fig. 5C). 
By contrast, EMSA tests revealed clearly that AgaR2 protein 
bound the other three AgaR2- binding palindromes in a 
dose- dependent manner (Fig. 5D–F). Additionally, we also 
used S. suis AgaR2 protein to evaluate the function of 
the two AgaR- binding sites in front of the EF1809 locus 
of E. faecalis V583, a close relative of S. suis. As a result, 
AgaR2 physically interacted with the EF1809 site 2, 
TTGTGGTTATAACCAGTT (Fig. 5H), but not the EF1809 
site 1, TTTATTGACAAAATAAAAAA (Fig. 5G) further 
validated the specificity of AgaR2 binding.
Different from the scenario with AgaR2, S. suis AgaR1 
was only found to have the ability to interact with the pre-
dicted SSU05_0448/9 site 1, TCTATTAATATACTAACACT 
(Fig. S3A). As anticipated from the comparative genomic 
analysis of the regulons, no interplay was observed between 
the AgaR2- specific SSU05_0448/9 site 2, 
TTGTGGTTATGTCCAGTA and S. suis AgaR1 protein (Fig. 
S3B), ruling out the possibility of cross- regulation by AgaR2 
and AgaR1. More importantly, the two putative AgaR1- 
recognizable sites from E. faecalis V583 (referred to EF814 
site 1, AAATTCAATATATTAAGATA and EF1809 site 1) 
were demonstrated to be functional, using gel shift assays 
with the S. suis AgaR1 protein (Fig. S3C and D).
Regulatory roles of AgaR2 (AgaR1) in 
Streptococcus GalNAc utilization
Given the observation that AgaR2 efficiently binds to the 
promoter regions of the three genes/operons (agaS 
(SSU05_0195), agaY (SSU05_1259), and bgaC (SSU05_0448)) 
encoding GalNAc utilization pathway in S. suis (Figs. 5, 
6A), we therefore attempted to elucidate its possible func-
tion in modulating Streptococcus GalNAc utilization ma-
chinery. The ΔagaR2 (Δ447) isogenic mutant was 
constructed, using an approach of homologous recombina-
tion, and its complementary strain CΔagaR2 (CΔ447) was 
generated through the low- copy plasmid pVA838- borne 
expression of agaR2 gene (Table S1). We noted that the 
deletion of agaR2 does not affect its growth (Fig. S1A). 
Additionally, no obvious alteration of capsule was observed 
in the Δ agaR2 mutant in comparison with the WT strain 
05ZYH33 (Fig. S1B and C). The qPCR- based transcriptional 
analyses showed that removal of agaR2 gene gave at least 
five-fold increment of agaS (agaAY and bgaC-gadVWEF 
operon) expression (Fig. 6B). Whereas the transcription of 
the above target genes was restored to the level seen in 
its parental strain S. suis 05ZYH33 (Fig. 6B). Similar results 
were also observed in altered expression profile of the 
ΔagaR2 mutant revealed by the RNA- Seq (e.g., expression 
of the three genes SSU05_0195 (agaS), SSU05_1259 (agaA), 
and SSU05_1258 (agaY) are elevated upon removal of agaR2, 
Table 1). Therefore, it seemed true that AgaR2 is a func-
tional repressor for the Streptococcus GalNAc utilization 
pathway. In contrast, we failed to visualize any significant 
alteration of the bgaC (SSU05_0448) expression level in 
the ΔagaR1 mutant in comparison with the WT strain and 
its complementary strain CagaR1 (not shown). The sug-
gested possibility that agaR1 might play an uncovered role 
or be an evolutional relic with loss of physiological demand 
and/or advantage, in that (1) there is no in vivo regulatory 
role attributed to its protein product AgaR1 although it 
retains DNA- binding activity to its own promoter, (2) the 
fact that all the other GalNAc metabolism- related genes 
are without control by AgaR1 is due to the lack of the 
predicted AgaR1- recognizable palindromes, (3) no physi-
ological function can be present in GalNAc metabolism, 
even AgaR1 can autoregulate itself. Thus, our subsequent 
interests focused on AgaR2 regulator.
Considering the direct relevance of AgaR2 to GalNAc 
utilization in S. suis, it is reasonable to probe the pos-
sibility whether this regulator acts to be responsive to 
the presence of GalNAc. We thereby grew WT strain S. 
suis 05ZYH33 in the medium with/without the supple-
mentation of GalNAc, and compared the expression profile 
of relevant target genes like agaS. As anticipated, the 
expression level of all the tested GalNAc catabolism 
pathway- encoding genes (including agaS and bgaC) was 
given a 5- to 10- fold increment upon the addition of 
10 mmol/L GalNAc into growth conditions (Fig. 6C). 
Together, we concluded that the GalNAc/GalN utilization 
pathway is repressed mainly by the AgaR2 regulator, 
whereas induced by an addition of GalNAc.
Table 1. RNA- Seq assays for expression profile of genes encoding N- acetyl- d- galactosamine utilization pathway.
Altered expression profile
Gene ID Function Ratio (ΔagaR2/WT) Up/down regulation P- value
05SSU0195 (agaS) Phosphosugar isomerase 6.20 Up 3.12836E- 261
05SSU1259 (agaA) N- acetylglucosamine- 6- phosphate deacetylase 3.12 Up 6.71E- 98
05SSU1258 (agaY) Tagatose 1,6- diphosphate aldolase 2.98 Up 1.27E- 151
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Contribution of AgaR2 (AgaR1) to bacterial 
pathogenesis
As we knew that amino sugars (GalN and/or GalNAc) 
constitute common residues for surface structure of vari-
ous bacterial cell walls (Bernatchez et al. 2005; Freymond 
et al. 2006), we thus ambitiously reasoned that (1) such 
a bacterial surface structure might be involved in mutual 
communication/crosstalk between bacterial pathogens and 
the inhabited/infected hosts, (2) the maintenance and 
regulation of GalN/GalNAc catabolism is probably impli-
cated into successful infections of some bacterial pathogens. 
To probe possible interference between GalN/GalNAc 
catabolism and the formation of virulence- associated sur-
face structures, we systemically employed two lines of 
approaches including cell lines- based tests and infections 
of experimental animals.
First, Hep- 2 cell line was used to evaluate the ability 
of bacterial adherence (Fig. 7A and B), and RAW264.7 
macrophage was subjected to dissecting its capability of 
anti- phagocytosis (Fig. 7C and D). Fluorescence- activated 
cell sorting (FACS)- based experiments elucidated that 
around threefold increment of bacterial adherence potential 
to Hep- 2 cells was given in the ΔagaR2 mutant relative 
to the WT 05ZYH33 strain (Fig. 7A and B). Furthermore, 
the deletion of agaR2 gene was found to give nearly 
Figure 7. Role of AgaR2- mediated regulation of GalNAc/GalN catabolism in bacterial virulence. (A) FACS- based visualization for a role of agaR2 
(ZYH05_0447) gene in adherence of Streptococcus suis 2 to Hep- 2 cells. (B) Quantitative analyses for effects of agaR2 deletion on adherence of S. 
suis 2 to Hep- 2 cells. (C) FACS- based visualization for the relevance of agaR2 gene to the ability of bacterial anti- phagocytosis against macrophage 
Raw264.7 cells. (D) Quantitative analyses for effects of agaR2 gene exerted on the ability of bacterial anti- phagocytosis against macrophage Raw264.7 
cells. (E) Evaluation for a role of agaR2 gene in bacterial virulence using infection model of mice. (F) Use of experimental infection of piglets to assay 
the relevance of agaR2 gene to bacterial pathogenesis. Note: P < 0.01. GalNAc, N- acetyl- d- galactosamine; GalN, galactosamine; FACS, fluorescence- 
activated cell sorting.
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fivefold increment of anti- phagocytosis ability against 
RAW264.7 macrophage (Fig. 7C and D). This finding 
was in much similarity to scenarios seen with both ΔneuB 
and Δcps2B mutants of S. suis 2 (note: the two genes are 
involved in bacterial surface architecture) (Feng et al. 
2012). Thereby, we anticipated that the enhancement in 
abilities of bacterial attachment and anti- phagocytosis might 
be partially due to the altered carbohydrates with GalN/
GalNAc residues on bacterial cell wall surface and this 
kind of alteration could be attributed to the dysfunction 
in AgaR2- mediated regulation of GalN/GalNAc utilization 
pathway. In contrast, no obvious difference between the 
ΔagaR1 mutant and its parental strain 05ZYH33 was ob-
served on either bacterial adherence to Hep- 2 cell line 
or bacterial anti- phagocytosis against RAW264.7 mac-
rophage (not shown). In fact, such a different effect exerted 
by AgaR2 (and AgaR1) is not very surprising, in that 
only Aga2 (not AgaR1) evolved to possess a regulatory 
role in controlling GalNAc catabolism in S. suis.
Given the fact that not only the two mutants (ΔneuB 
and Δcps2B) of S. suis 2 feature the potential of both in-
creased adherence/anti- phagocytosis, but also exhibit dra-
matically reduced virulence in infection models of both 
mice and piglets (Feng et al. 2012), it is of much interest 
to further probe a possible role of agaR2 in bacterial viru-
lence. In the mice infection assays, all the 10 BALB/c (4- 
week old, female) mice infected with the WT strain 05ZYH33 
were sick shortly, and most of the rats died within 60 h 
(Fig. 7E). By contrast, mice of the negative control group 
inoculated with THB survived (not shown). In particular 
note, nearly all the mice infected with the ΔagaR2 mutant 
survived, while most of animals injected with the comple-
mentary strain CΔagaR2 died within 3 days. To verify the 
results obtained from the above model of mice, we repeated 
the infection tests using the model of SPF- piglets, natural 
hosts for S. suis. As a result, we observed that the six 
SPF- piglets inoculated with WT virulent strain developed 
most of the typical disease symptoms (high fever, limping, 
swollen joints, etc.), and most of them died on day 1 
(Fig. 7F). As expected, all the piglets infected with the 
ΔagaR2 mutant survived during the period of entire experi-
ment. However, the re- introduction of agaR2 gene into 
the ΔagaR2 mutant restored fully its strong virulence 
(Fig. 7F). Collectively, we believed that the prevalent regu-
lator AgaR2 for GalN/GalNAc utilization pathway contrib-
utes to bacterial infectivity of S. suis, although we failed 
to note an apparent role of the other secondary regulator 
AgaR1 in bacterial pathogenicity (not shown).
Discussion
The data shown here represents a first report that il-
lustrated the genomic reconstruction of GalN/GalNAc 
catabolism pathway in Streptococci and Firmicutes. Different 
from the scenarios described in E. coli (Reizer et al. 1996) 
and Shewanella (Leyn et al. 2012), a significant variation 
of this pathway was proposed for Streptococci (Fig. 1 and 
Table S4). As you can see from the working model, AgaZ 
is absent in S. suis. It seemed likely that our continued 
genomic analyses pointed out that S. suis actually lacks 
any ortholog of this gene. Thereby, we speculated that 
the loss of AgaZ function in S. suis might be compensated 
by two other genes that are not in aga regulon: (1) 
SSU05_1041 (lacC2; tagatose 6- phosphate kinase, EC 
2.7.1.144), (2) SSU05_0543 (pfk, 6- phosphofructokinase, 
EC 2.7.1.11). This hypothesis required further experimental 
verification.
Through extensive analyses for genomic contexts from 
Firmicutes, we dissected two GalN/GalNAc pathway- 
specific regulators namely AgaR2 and AgaR1. The agaR1 
gene is divergently transcribed into genes forming an 
operon and encoding a β- galactosidase (BgaC) (Hu et al. 
2014) and a PTS sugar uptake system (named agaBCDE 
that could be a GalN uptake system). The agaR2 gene 
in many Streptococcus species is located in front of the 
genes encoding the predicted galactosamine- 6- phosphate 
isomerase and Tagatose 1,6- diphosphate aldolase, two key 
enzymes in the AGA catablic pathway. In S. suis, the 
locus SSU05_0448 is annotated to be agaR1, whereas 
SSU05_0447 is referred to agaR2. Somewhat evolutionally 
distinct from the paradigm regulator (the E. coli agaR 
protein product) that belongs to the DeoR family of 
transcription factor, the two newly identified regulators 
AgaR2 and AgaR1 are classified into the GntR family of 
transcription repressors (Figs. 3, S1). Additionally, it 
seemed likely that the two GntR- like regulators (AgaR2 
and AgaR1) themselves fit into two different subgroups 
and might possess the varied preference in their DNA- 
binding sites (Figs. 3, S4). The fact that AgaR2- recognizable 
palindrome is predicted to be present in front of multiple 
target genes whereas AgaR1 has only one site located in 
its own promoter region (Fig. 2) raised the possibility 
that AgaR2 could have been evolved into a prevalent/
major regulator for GalN/GalNAc utilization pathway 
(AgaR1 might be a minor/and even a cryptic regulator). 
Our in vitro gel shift assays validated the direct interac-
tion between the AgaR2 (and/or AgaR1) protein and its 
binding sites (Figs. 5, S3). Given the facts that a significant 
regulated expression of GalN/GalNAc utilization- related 
genes (such as agaS, agaAY , and bgaC) by AgaR2 was 
observed, however, no in vivo role could be attributed 
to AgaR1, we came to be more confident that AgaR2 
relative to AgaR1 acts as a prevalent/leading player in 
modulating expression of genes encoding bacterial GalN/
GalNAc catabolism in most Firmicutes. However, we did 
not obtain evidence for physiological ligand/molecular 
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effector of AgaR2 repressor, although we observed that 
GalNAc does induce the expression of GalN/GalNAc 
catabolism- related genes such as agaS (Fig. 6C).
The essence that amino sugars (GalN and/or GalNAc) 
are common components on the surface of bacterial cell 
walls (Bernatchez et al. 2005; Freymond et al. 2006) has 
driven us to test possible roles for the regulation of GalN/
GalNAc catabolism in the infectivity of bacterial pathogens. 
As expected, an interference of GalN/GalNAc catabolism/
utilization by disrupting agaR2 encoding a prevalent regu-
lator, significantly altered abilities of both bacterial adher-
ence to Hep- 2 cells and anti- phagocytosis against 
RAW264.7 macrophage (Fig. 7). Given the fact that in 
this alteration we observed a similar scenario seen with 
the two virulence- associated determinants (neuB and cps2B) 
with biological roles in constitution/development of bacte-
rial surface architecture (Feng et al. 2012), we reasoned 
that regulation/maintenance of GalN/GalNAc catabolism 
pathway is essential for full virulence of S. suis. In fact, 
this proposal was subsequently proved in that the dys-
function in AgaR2- mediated regulation impairs bacterial 
infectivity of S. suis in both mice and piglets (Fig. 7). 
Also, we are not surprised to establish the relevance of 
GalN/GalNAc catabolism to bacterial pathogenicity, in that 
the alteration of carbohydrates with GalN/GalNAc residues 
on bacterial cell surface interferes with the bacterial 
pathogen- binding host cells.
Taken together, we are first to report the genomic re-
construction of the GalN/GalNAc utilization pathway in 
S. suis and its novel regulatory network with variations. 
More intriguingly, we revealed that the interference of 
GalN/GalNAc utilization pathway by the inactivation of 
the AgaR2 regulator attenuates greatly the bacterial in-
fectivity of the zoonotic pathogen S. suis. Our finding 
might provide a metabolic basis for design of small mol-
ecule drugs (inhibitors)- based therapeutics against S. suis 
infection through targeting the regulatory network of GalN/
GalNAc utilization pathway.
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final output is generated by the ESPript 2.2 program (http://
espript.ibcp.fr/ESPript/cgi-bin/ESPript.cgi). Identical resi-
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profile of the purified AgaR1 (SSU05_0448) protein from 
Streptococcus suis. (B) Western blot analyses for the N- 
terminal 6x his tagged AgaR1 protein, using the anti- 
6xHis tag primary antibody. The monomeric protein 
with expected size of ~30 kDa is indicated with an 
arrow, whereas the dimer form (~60 kDa) is highlighted 
with an asterisk. Designations: M, protein standard 
marker; WB, western blot. (C) Determination for the 
solution structure of the AgaR1 protein, using chemical 
cross- linking assays. The chemical cross- linker used here 
is ethylene glycol bis- succinimidylsuccinate (EGS). The 
triangle on the top represents the addition of the EGS 
cross- linker in varied concentrations (0.1, 0.2, 0.5, 1.0, 
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Figure S3. Binding of AgaR1 to the predicted palindromes. 
The predicted AgaR1- binding site (in A) of SSU05_0448/9 
gene bound AgaR1 (SSU05_0448) protein, whereas the 
AgaR2- binding site (in B) of this locus does not interact 
with AgaR1 protein. (C) Streptococcus suis AgaR1 protein 
bound to the predicted AgaR1 site of EF814 gene from 
Enterococcus faecalis V583. (D) S. suis AgaR1 protein bound 
to the putative AgaR1 site of EF1809 gene from E. faecalis 
V583. The minus sign denotes no addition of AgaA1 
protein. The protein levels of AgaR2 (on the right- hand 
four lanes of each panel [left to right]) were 0.5, 1, 2, 
and 5 pmol. The protein samples were incubated with 
0.2 pmol of the DIG- labeled probe in a total volume of 
15 μL. A representative result from three independent gel 
shift assays (7% native PAGE) is given.
Figure S4. Phylogenetic analyses of phosphotransferase 
system (PTS). In total, the PTS system is classified into 
five sub- groups, one of which is PTS- V (highlighted in 
blue). Locus tag of PTS system is showed here for AgaC, 
SSU05_0451 is indicated in red.
